Summary of Genmab's Conference Call Company Overview - **Company**: Genmab - **Event**: 46th Annual TD Cowen Healthcare Conference - **Key Speakers**: Anthony Pagano (CFO and Executive VP), Yaron Werber (Biotech Team) Core Industry Insights - **Oncology Focus**: Genmab is heavily invested in oncology, with three late-stage programs: EPKINLY, Rina-S, and pidocentimab, all of which have received FDA Breakthrough Therapy designations [2][3] - **Revenue Growth**: The company is experiencing strong revenue growth, particularly from proprietary products like EPKINLY and TIVDAK, with an increasing percentage of recurring revenue [7][8] - **Future Projections**: Genmab anticipates continued revenue growth into 2026 and beyond, driven by the success of its late-stage programs and a robust internal pipeline [3][4] Financial Performance - **Revenue Profile**: The revenue quality has improved year-over-year, with a notable increase in the contribution from proprietary products [7] - **TIVDAK Performance**: TIVDAK is expected to remain flat in terms of growth, contributing approximately $20 million, while EPKINLY is the primary driver of revenue growth [9][12] - **EPKINLY Sales**: EPKINLY had global sales of DKK 468 million last year, with expectations for growth in 2026, particularly in the second-line follicular lymphoma segment [17][19] Product Pipeline and Launches - **Rina-S and pidocentimab**: Both are expected to have registrational readouts in the second half of 2026, with potential launches in 2027 or 2028 [21][22] - **Market Potential**: Rina-S has a peak sales potential of over $2 billion, while EPKINLY is projected to reach $3 billion [27][31] - **Regulatory Process**: The timeline for product launches will depend on the regulatory process following data readouts [22][23] Debt and Profitability - **Debt Management**: Genmab took on $5.5 billion of debt for the Mirati acquisition and aims to reduce gross leverage to below 3 times by the end of 2027 [39][40] - **Profitability Commitment**: The company is committed to maintaining significant profitability in 2026 and 2027, focusing on efficient investments and operational productivity [40][41] Royalty Contributions - **Royalty Business**: The royalty revenue is primarily driven by DARZALEX and Kesimpta, with expectations for growth in 2026 [58][59] - **Emerging Products**: Tecfidera is expected to contribute positively, although it remains a smaller product in the portfolio [58] Additional Insights - **Synergy Realization**: The acquisition of Mirati is not primarily synergy-driven, but Genmab is looking for productivity improvements across its business [55][56] - **Clinical Trial Dynamics**: The company is open to adjusting clinical trial parameters to enhance outcomes and timelines [24][25] This summary encapsulates the key points discussed during the conference call, highlighting Genmab's strategic focus on oncology, financial performance, product pipeline, and future growth prospects.